2001 (animal lipolysis data, no pediatric data) Monitoring requirement / Height velocity, Tanner staging, fasting glucose, and IGF-1 every 3 months minimum FDA pediatric weight-management approvals / Orlistat (age 12+), liraglutide 3 mg (age 12+), semaglutide 2.4 mg (age 12+) Mental health screen / Mandatory at baseline and every visit per AAP obesity guidelines What Is AOD-9604 and Why Is It Being Asked About in Adolescents
Specifications Specifications By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form
The clinical trial results didn't support the efficacy needed for an obesity drug approval
Weeks 812+: Longer-term repair, mobility, and maintenance benefits may continue to build gradually
Seutter E et al
He's mentioned it dozens of times across podcast episodes, often with genuine enthusiasm about its healing effects